Aggressive Fibromatosis clinical trials at UC Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This study evaluates nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo.